3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
52
pembrolizumab
26
Nivolumab
20
Bevacizumab
19
Radiosurgery
17
Doxorubicin
12
atezolizumab
9
Erlotinib Hydrochloride
9
lenvatinib
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
tremelimumab
6
durvalumab
6
Ramucirumab
6
Radiofrequency Ablation
6
Cisplatin
6
Sunitinib
5
tislelizumab
4
regorafenib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Everolimus
4
Capecitabine
4
nintedanib
3
fluoromisonidazole
3
carotuximab
3
bavituximab
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Hepatocellular
×
orantinib
×
Clear all
NCT01465464
2019-08-07
ORIENTAL
Taiho Pharmaceutical Co., Ltd.
Phase 3
Terminated
888 enrolled
12 charts